|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMX4 |
Gene summary for TMX4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMX4 | Gene ID | 56255 |
| Gene name | thioredoxin related transmembrane protein 4 | |
| Gene Alias | DJ971N18.2 | |
| Cytomap | 20p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H1E5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56255 | TMX4 | LZE4T | Human | Esophagus | ESCC | 1.34e-09 | 4.67e-01 | 0.0811 |
| 56255 | TMX4 | LZE20T | Human | Esophagus | ESCC | 8.61e-03 | 1.76e-01 | 0.0662 |
| 56255 | TMX4 | LZE24T | Human | Esophagus | ESCC | 2.45e-10 | 2.60e-01 | 0.0596 |
| 56255 | TMX4 | P1T-E | Human | Esophagus | ESCC | 2.87e-11 | 6.83e-01 | 0.0875 |
| 56255 | TMX4 | P2T-E | Human | Esophagus | ESCC | 7.27e-53 | 1.08e+00 | 0.1177 |
| 56255 | TMX4 | P4T-E | Human | Esophagus | ESCC | 5.75e-15 | 4.04e-01 | 0.1323 |
| 56255 | TMX4 | P5T-E | Human | Esophagus | ESCC | 7.47e-06 | 5.41e-02 | 0.1327 |
| 56255 | TMX4 | P8T-E | Human | Esophagus | ESCC | 1.51e-20 | 4.93e-01 | 0.0889 |
| 56255 | TMX4 | P9T-E | Human | Esophagus | ESCC | 6.61e-11 | 3.50e-01 | 0.1131 |
| 56255 | TMX4 | P10T-E | Human | Esophagus | ESCC | 2.44e-29 | 5.49e-01 | 0.116 |
| 56255 | TMX4 | P11T-E | Human | Esophagus | ESCC | 1.94e-23 | 1.02e+00 | 0.1426 |
| 56255 | TMX4 | P12T-E | Human | Esophagus | ESCC | 9.05e-16 | 1.89e-01 | 0.1122 |
| 56255 | TMX4 | P15T-E | Human | Esophagus | ESCC | 4.58e-04 | 1.60e-01 | 0.1149 |
| 56255 | TMX4 | P16T-E | Human | Esophagus | ESCC | 2.19e-65 | 1.33e+00 | 0.1153 |
| 56255 | TMX4 | P17T-E | Human | Esophagus | ESCC | 5.31e-07 | 6.04e-01 | 0.1278 |
| 56255 | TMX4 | P19T-E | Human | Esophagus | ESCC | 1.41e-04 | 4.93e-01 | 0.1662 |
| 56255 | TMX4 | P20T-E | Human | Esophagus | ESCC | 3.63e-18 | 4.29e-01 | 0.1124 |
| 56255 | TMX4 | P21T-E | Human | Esophagus | ESCC | 5.83e-24 | 4.91e-01 | 0.1617 |
| 56255 | TMX4 | P22T-E | Human | Esophagus | ESCC | 1.03e-18 | 3.36e-01 | 0.1236 |
| 56255 | TMX4 | P23T-E | Human | Esophagus | ESCC | 3.64e-12 | 3.82e-01 | 0.108 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMX4 | SNV | Missense_Mutation | c.185C>T | p.Pro62Leu | p.P62L | Q9H1E5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TMX4 | SNV | Missense_Mutation | novel | c.201C>G | p.Cys67Trp | p.C67W | Q9H1E5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| TMX4 | SNV | Missense_Mutation | c.337N>T | p.His113Tyr | p.H113Y | Q9H1E5 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| TMX4 | SNV | Missense_Mutation | novel | c.871G>A | p.Glu291Lys | p.E291K | Q9H1E5 | protein_coding | tolerated(0.07) | benign(0.089) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| TMX4 | SNV | Missense_Mutation | c.887N>T | p.Ala296Val | p.A296V | Q9H1E5 | protein_coding | tolerated(0.27) | benign(0) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMX4 | SNV | Missense_Mutation | novel | c.685N>C | p.Asn229His | p.N229H | Q9H1E5 | protein_coding | tolerated(0.54) | benign(0.135) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TMX4 | SNV | Missense_Mutation | c.155N>T | p.Glu52Val | p.E52V | Q9H1E5 | protein_coding | deleterious(0) | benign(0.44) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMX4 | SNV | Missense_Mutation | novel | c.1030N>T | p.His344Tyr | p.H344Y | Q9H1E5 | protein_coding | tolerated(0.33) | benign(0.027) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMX4 | SNV | Missense_Mutation | rs111982452 | c.916N>A | p.Gly306Ser | p.G306S | Q9H1E5 | protein_coding | tolerated(1) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TMX4 | SNV | Missense_Mutation | rs376577418 | c.689N>A | p.Arg230Gln | p.R230Q | Q9H1E5 | protein_coding | tolerated(0.83) | benign(0) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |